News Releases

IGF Oncology to Present at Biotech Showcase 2019

ST. PAUL, Minn., Dec. 20, 2018 /PRNewswire/ -- IGF Oncology, a clinical-stage company developing targeted therapies for cancer, today announced that its Founder and President, Hugh McTavish, Ph.D., will present at Biotech Showcase 2019, held January 6-9, 2019, at the Hilton San Francisco Union Square.

Dr. McTavish will present IGF Oncology's clinical pipeline, including its lead product, IGF-MTX, a conjugate of FDA-approved methotrexate with a proprietary derivative of insulin-like growth factor-1 (IGF) that is used to target the therapy to cancer cells that over-express the IGF receptor.

Details of IGF Oncology's presentation are as follows:


Biotech Showcase 2019


Wednesday, January 9, 2019


10 a.m. (Pacific Time)


Hilton San Francisco Union Square

About IGF Oncology
IGF Oncology is a clinical-stage company developing targeted therapies for cancer. The Company's lead product, IGF-MTX, is a conjugate of the drug methotrexate and a proprietary recombinant protein derivative of insulin-like growth factor-1 (IGF), the receptor for which is over-expressed by a number of cancers. A clinical study showed that IGF-MTX was effective at a concentration 12-fold lower than the lowest prescribed dose of methotrexate, across multiple tumor types, and without the dose-limiting side effect of cytopenia. The Company is currently conducting a Phase 1b/2a study with the Mayo Clinic in patients with myelodysplastic syndrome (MDS) and raising additional capital to fund this asset through potential approval.


Tiberend Strategic Advisors, Inc. 
Brian Pinkston (Investors) 
(212) 375-6298

David Schemelia (Media) 
(212) 375-2686